Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer that has spread or cannot be removed by surgery.
- Your cancer has a high level of the PD-L1 protein (CPS score of 10 or higher).
- You have not had any prior chemotherapy or other systemic treatment for advanced breast cancer.
- You are well enough to perform daily activities (ECOG score 0 or 1).
- You have measurable tumors that can be seen on scans.
- You are willing to provide a tumor sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
This study is looking at a new antibody-drug treatment (Dato-DXd) for people with triple-negative breast cancer that has spread and hasn't been treated yet. It's designed to attack cancer cells directly and may be an option for those who can't have immunotherapy.
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.